<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01007994</url>
  </required_header>
  <id_info>
    <org_study_id>09-054</org_study_id>
    <nct_id>NCT01007994</nct_id>
  </id_info>
  <brief_title>Reduction of Night-time Blood Pressure in Pediatric Renal Transplant Recipients</brief_title>
  <official_title>Reduction of Nocturnal Hypertension in Pediatric Renal Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study will investigate the effect of chronotherapeutic alteration of
      anti-hypertensive medication on nocturnal hypertension and end-organ injury in pediatric
      renal transplant recipients who are non-dippers. Additionally, the investigators aim to
      examine the association between response to intervention, serum adiponectin levels and
      adiponectin gene polymorphisms. The investigators hypothesize that (1) evening administration
      of anti-hypertensive medication will convert subjects from non-dipper to dipper status,
      improve mean nocturnal blood pressure (BP), and improve nocturnal BP load, (2) evening
      administration of anti-hypertensive medication will reduce albuminuria, left ventricular mass
      index (LVMI), rate of decline of glomerular filtration rate (eGFR) and will decrease pulse
      wave velocity (PWV), and (3) lower adiponectin levels and presence of adiponectin gene
      polymorphisms will be associated with less of a response to the intervention.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects in each of the treatment arms who change from non-dipper to dipper status</measure>
    <time_frame>3 months and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in night-time systolic/diastolic blood pressure</measure>
    <time_frame>3 months and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular mass index</measure>
    <time_frame>3 months and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in albumin:creatinine ratio</measure>
    <time_frame>3 months and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in estimated glomerular filtration rate</measure>
    <time_frame>3 months and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pulse wave velocity</measure>
    <time_frame>3 months and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of serum adiponectin levels and SNPs of adiponectin with outcomes</measure>
    <time_frame>3 months and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Hypertension Secondary to Kidney Transplant</condition>
  <arm_group>
    <arm_group_label>New Medication</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A new anti-hypertensive medication (enalapril, propranolol or isradipine) will be added at 8pm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects in the control group will continue to take their medications as usual.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>New Medication: Enalapril, Isradipine, Propranolol</intervention_name>
    <description>Enalapril will be added in the evening at 8 pm. If the subject is already on an ACEI or there is a contraindication to starting an ACEI the subject will be started on isradipine instead. If the subject is already on an ACEI and calcium channel blocker at baseline, propranolol will then be the new medication added.
Dosing will be as follows:
ACEI: Enalapril &lt; 40 kg starting dose 2.5 mg titrate to 5 mg &gt; 40 kg starting dose 5 mg titrate to 10mg Calcium Channel Blocker: Isradipine &lt; 40 kg 2.5 mg &gt; 40 kg starting dose 2.5 mg titrate to 5 mg Beta Blocker: Propranolol &lt;40 kg starting dose 10 mg titrate to 20 mg &gt;40 kg starting dose 20 mg titrate to 40 mg</description>
    <arm_group_label>New Medication</arm_group_label>
    <other_name>Vasotec, DynaCirc, Inderal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects age 5-21 years

          -  Stable kidney transplant recipients (&lt;30% change in eGFR in past 3 months)

          -  eGFR &gt; 30 ml/min/1.73 m2

          -  &gt;6 months since kidney transplant

          -  ABPM: Non-dipper status defined as &lt;10% decline in systolic or diastolic blood
             pressure from daytime to night-time

        Exclusion Criteria:

          -  ABPM: Subjects with daytime mean blood pressure &gt; 95% for height and sex

          -  Subjects on diuretic monotherapy will not be eligible for the time change group (to
             avoid discomfort of nocturnal enuresis)

          -  Subjects with nephrotic range proteinuria

          -  Subjects with major co-morbid conditions such as cardiac disease, pulmonary disease
             and diabetes mellitus

          -  Subjects/guardians or subjects who, in the opinion of the Investigator, may be
             non-compliant with study schedules or procedures

          -  Subjects who are pregnant will not be eligible for the new medication group
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine B Sethna, MD, EdM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwell Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cohen Children's Medical Center of NY</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2009</study_first_submitted>
  <study_first_submitted_qc>November 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2009</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwell Health</investigator_affiliation>
    <investigator_full_name>Christine B Sethna, MD</investigator_full_name>
    <investigator_title>Division Director, Pediatric Nephrology</investigator_title>
  </responsible_party>
  <keyword>Nocturnal hypertension</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Renal Transplant</keyword>
  <keyword>Pulse Wave Velocity</keyword>
  <keyword>Echocardiogram</keyword>
  <keyword>Pediatric Renal Transplant Recipient</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
    <mesh_term>Isradipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

